Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank De Wolf

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2008
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort studyFerdinand W N M Wit, Anouk M Kesselring, Luuk Gras, et al.
AIDS (London, England)|October 3, 2003
Mortality and progression to AIDS after starting highly active antiretroviral therapyArd I van Sighem, Mark A van de Wiel, Azra C Ghani, et al.
AIDS (London, England)|December 22, 2007
Combination antiretroviral therapy failure and HIV super-infectionDaniela Bezemer, Ard van Sighem, Frank de Wolf, et al.
AIDS (London, England)|June 3, 2009
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapyAnouk M Kesselring, Ferdinand W Wit, Caroline A Sabin, et al.
AIDS Research and Human Retroviruses|April 10, 2010
Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infectionRadjin Steingrover, Evian Fernandez Garcia, Irene G M van Valkengoed, et al.
Plos One|October 8, 2013
The presence of CXCR4-using HIV-1 prior to start of antiretroviral therapy is an independent predictor of delayed viral suppressionEsther F Gijsbers, Ard van Sighem, Agnes M Harskamp, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
AIDS (London, England)|December 17, 2009
Transmission networks of HIV-1 among men having sex with men in the NetherlandsDaniela Bezemer, Ard van Sighem, Vladimir V Lukashov, et al.
Antiviral Therapy|November 18, 2009
Safety and efficacy of once-daily nevirapine dosing: a multicohort studyAlexandra Calmy, Nathalie Vallier, Alain Nguyen, et al.
Plos Medicine|November 4, 2015
Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic AnalysisDaniela Bezemer, Anne Cori, Oliver Ratmann, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2008
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort studyFerdinand W N M Wit, Anouk M Kesselring, Luuk Gras, et al.
AIDS (London, England)|October 3, 2003
Mortality and progression to AIDS after starting highly active antiretroviral therapyArd I van Sighem, Mark A van de Wiel, Azra C Ghani, et al.
AIDS (London, England)|December 22, 2007
Combination antiretroviral therapy failure and HIV super-infectionDaniela Bezemer, Ard van Sighem, Frank de Wolf, et al.
AIDS (London, England)|June 3, 2009
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapyAnouk M Kesselring, Ferdinand W Wit, Caroline A Sabin, et al.
AIDS Research and Human Retroviruses|April 10, 2010
Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infectionRadjin Steingrover, Evian Fernandez Garcia, Irene G M van Valkengoed, et al.
Plos One|October 8, 2013
The presence of CXCR4-using HIV-1 prior to start of antiretroviral therapy is an independent predictor of delayed viral suppressionEsther F Gijsbers, Ard van Sighem, Agnes M Harskamp, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
AIDS (London, England)|December 17, 2009
Transmission networks of HIV-1 among men having sex with men in the NetherlandsDaniela Bezemer, Ard van Sighem, Vladimir V Lukashov, et al.
Antiviral Therapy|November 18, 2009
Safety and efficacy of once-daily nevirapine dosing: a multicohort studyAlexandra Calmy, Nathalie Vallier, Alain Nguyen, et al.
Plos Medicine|November 4, 2015
Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic AnalysisDaniela Bezemer, Anne Cori, Oliver Ratmann, et al.
Pageof 11